Journal of Neuroendovascular Therapy
Online ISSN : 2186-2494
Print ISSN : 1882-4072
ISSN-L : 1882-4072
Original Article
Thrombectomy for Anterior Circulation Stroke with a Hybrid Cell Design Stent Retriever: A Multicenter Registry
Luís Henrique de Castro-Afonso Felipe Padovani TrivelatoEduardo WajnbergEduardo Siqueira WaihrichThiago Giansante AbudSaulo Villas Boas AlvesAnderson MatsubaraMarco Tulio Salles RezendeJoão Francisco Santoro AraujoGuilherme Seizem NakiriDaniel Giansante Abud
Author information
JOURNAL OPEN ACCESS

2025 Volume 19 Issue 1 Article ID: oa.2024-0083

Details
Abstract

Objective: Thrombectomy is the standard recanalization treatment for acute ischemic stroke (AIS) due to large vessel occlusions (LVO). However, thrombectomy was validated using a few brands of devices. New types of thrombectomy devices have been developed, and assessing their safety and efficacy is essential. This study aimed to evaluate the safety and efficacy of thrombectomy with the Aperio Hybrid stent retriever (Acandis, Pforzheim, Germany) in the treatment of patients with AIS due to anterior circulation LVO.

Methods: This was a multicenter registry of thrombectomy in the treatment of stroke due to anterior circulation LVO. Between January 2022 and January 2024, a total of 128 patients were included.

Results: The mean procedure time was 62 minutes. The rates of the main outcomes were recanalization (extended treatment in cerebral ischemia 2b-3) 102/128 (79.7%), symptomatic intracranial hemorrhage 9/128 (7.0%), good clinical outcome (modified Rankin Scale = 0–2) 67/128 (52.3%), and mortality 24/128 (18.7%) at 3 months.

Conclusion: This study showed that, in a multicenter real-life scenario, the Aperio hybrid stent retriever was safe and effective for thrombectomy of anterior circulation strokes. The outcomes of this study were similar to those of previous large thrombectomy studies.

Content from these authors
© 2025 The Japanese Society for Neuroendovascular Therapy

This article is licensed under a Creative Commons [Attribution-NonCommercial-NoDerivatives 4.0 International] license.
https://creativecommons.org/licenses/by-nc-nd/4.0/
Previous article Next article
feedback
Top